Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema

Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema

In the Phase 1b study, at 27,000 ng/mL (corresponding to approximate drug levels at Day 22 for 300 mg DX-2930), 2-chain high-molecular-weight kininogen was suppressed to a level approximating that observed in healthy subjects.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB252-AB252
Hauptverfasser: Wedner, H. James, MD FAAAAI, Busse, Paula J., MD FAAAAI, Banerji, Aleena, MD, Shennak, Mustafa, Lumry, William R., MD FAAAAI, Davis-Lorton, Mark A., MD FAAAAI, Jacobs, Joshua S., MD, Baker, James W., MD FAAAAI, Bernstein, Jonathan A., MD, Lockey, Richard F., MD, Li, H. Henry, MD PhD, Craig, Timothy J, Cicardi, Marco, Riedl, Marc A., MD MS, Al-Ghazawi, Ahmad, Soo, Carolyn, Iarrobino, Ryan, Sexton, Daniel, TenHoor, Christopher, Faucette, Ryan, Biedenkapp, Joseph C, Chyung, Yung H, Adelman, Burt
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Drug dosages
HIV
Human immunodeficiency virus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the Phase 1b study, at 27,000 ng/mL (corresponding to approximate drug levels at Day 22 for 300 mg DX-2930), 2-chain high-molecular-weight kininogen was suppressed to a level approximating that observed in healthy subjects.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.909